...
【24h】

Nonsteroidal selective androgen receptor modulators enhance female sexual motivation.

机译:非甾体选择性雄激素受体调节剂可增强女性的性动机。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Women experience a decline in estrogen and androgen levels after natural or surgically induced menopause, effects that are associated with a loss of sexual desire and bone mineral density. Studies in our laboratories have shown the beneficial effects of selective androgen receptor modulators (SARMs) in the treatment of osteoporosis and muscle wasting in animal models. A series of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-cyano-3-trifluoromethyl-phenyl)-propionamid e analogs was synthesized to evaluate the effects of B-ring substitutions on in vitro and in vivo pharmacologic activity, especially female sexual motivation. The androgen receptor (AR) relative binding affinities ranged from 0.1 to 26.5% (relative to dihydrotestosterone) and demonstrated a range of agonist activity at 100 nM. In vivo pharmacologic activity was first assessed by using male rats. Structural modifications to the B-ring significantly affected the selectivity of the SARMs, demonstrating that single-atom substitutions can dramatically and unexpectedly influence activity in androgenic (i.e., prostate) and anabolic (i.e., muscle) tissues. (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro,4-chlorophenoxy)-2-hydroxy-2 -methyl-propanamide (S-23) displayed full agonist activity in androgenic and anabolic tissues; however, the remaining SARMs were more prostate-sparing, selectively maintaining the size of the levator ani muscle in castrated rats. The partner-preference paradigm was used to evaluate the effects of SARMs on female sexual motivation. With the exception of two four-halo substituted analogs, the SARMs increased sexual motivation in ovariectomized rats, with potency and efficacy comparable with testosterone propionate. These results indicate that the AR is important in regulating female libido given the nonaromatizable nature of SARMs and it could be a superior alternative to steroidal testosterone preparations in the treatment of hypoactive sexual desire disorder.
机译:妇女在自然或手术引起的更年期后会经历雌激素和雄激素水平的下降,这与性欲和骨矿物质密度的降低有关。我们实验室的研究表明,选择性雄激素受体调节剂(SARM)在治疗动物模型中的骨质疏松和肌肉萎缩方面具有有益作用。合成了一系列S-3-(苯氧基)-2-羟基-2-甲基-N-(4-氰基-3-三氟甲基-苯基)-丙酰胺类似物以评估B环取代对体外的影响以及体内药理活性,尤其是女性的性动机。雄激素受体(AR)的相对结合亲和力范围为0.1至26.5%(相对于二氢睾丸激素),并在100 nM时表现出一定范围的激动剂活性。首先通过使用雄性大鼠评估体内药理活性。对B环的结构修饰显着影响了SARM的选择性,表明单原子取代会极大且出乎意料地影响雄激素(即前列腺)和合成代谢(即肌肉)组织中的活性。 (S)-N-(4-氰基-3-三氟甲基-苯基)-3-(3-氟,4-氯苯氧基)-2-羟基-2-甲基丙酰胺(S-23)在雄激素中表现出完全的激动剂活性和合成代谢组织;然而,剩余的SARMs保留了更多的前列腺,选择性地维持了cast割大鼠的肛提肌的大小。伙伴偏好模式用于评估SARM对女性性动机的影响。除了两个四卤代类似物外,SARMs增加了去卵巢大鼠的性动机,其效力和功效与丙酸睾丸激素相当。这些结果表明,鉴于SARM的非芳香化性质,AR在调节女性性欲方面很重要,在治疗性欲减退方面,它可能是甾体睾丸激素制剂的替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号